it could unlock significant upside in its share price just as the weight-loss treatments did for Eli Lilly and Novo Nordisk. It’s also worth mentioning that Merck is focusing on an oral pill ...

The round is one of Europe’s largest-ever biotech VC deals, signalling investor appetite for the booming weight loss market.

Researchers from Canada reviewed the results of 26 trials to determine which of the weight loss jabs are the most effective ...

Medicare now covers Eli Lilly's Zepbound for obstructive sleep apnea, FDA-approved for obesity and sleep apnea treatment, ...

Dual- and triple-agonist GLP-1s appear to achieve greater weight loss in an overview of clinical trials of approved and ...

Eli Lilly’s popular anti-obesity drug Zepbound could get a sales boost after the U.S. Medicare program decided to pay for its use to treat sleep apnea. The Centers f ...

A UK biotechnology startup is entering the crowded obesity drug market, armed with $411 million and a promising ...

Eli Lilly will seek to have Mounjaro listed on the scheme this year. If successful, it would mean taxpayer subsidies for the ...